CLX Is Down 26%. The Dividend Is Not.

Start with the chart and you would never buy this stock.

Clorox peaked near $132 over the past 52 weeks. It is sitting around $98 right now. That is a 26% drawdown while the S&P 500 was grinding higher. In consumer staples terms, that kind of underperformance does not happen quietly. Something went wrong. Actually, several things went wrong at the same time, which is part of why the selling has been as persistent as it has been. A multiyear ERP system overhaul that was messier than anyone wanted to admit. A cyberattack in 2023 that left deeper operational scars than the company initially telegraphed. A $2.25 billion acquisition of GOJO Industries that the market is still figuring out how to value. A $476 million buyout of P&G’s 20% stake in the Glad business. A guidance cut that took full-year adjusted EPS from a $5.60 to $5.95 range all the way down to $4.78 to $4.98. And then, right in the middle of all of it, the CEO announced she is stepping down for health reasons. That is an unusual amount of turbulence for a company that sells bleach and trash bags.

The dividend, though. That part has not moved.

48 consecutive years of raises. Annual payout of $4.96 per share. Current yield of 5.3%, which is nearly two full percentage points above the 5-year average yield of 3.31%. When a yield gap that wide opens up on a Dividend Aristocrat, it usually means one of two things: the dividend is about to get cut, or the stock fell and the payout held. This looks like the second one. Free cash flow margin averaged 11.1% over the last two years on a $7 billion revenue base. That is real cash. The payout ratio is elevated, above 80%, which is worth watching, but management has been explicit about protecting the dividend through this transition. 48 years of consecutive raises does not get abandoned without a fight.

Q3 fiscal year 2026 results landed on April 30th. Net sales of $1.67 billion came in flat year over year. Adjusted EPS of $1.64 beat estimates by roughly 6%. Those two data points sound fine. The part people skip: gross margin fell 140 basis points to 43.2%, organic sales declined 1%, and the full-year guidance got cut significantly. The culprits were higher manufacturing costs, logistics pressure, and the inventory step-up charges that come with absorbing a large acquisition mid-integration. Q4 FY2026 is the next real data point. That is when the full GOJO cost structure hits the income statement in one shot. Worth marking your calendar.

Here is where I am at on the business itself. Clorox has been around since 1913. It started with a single bleach product. Today it runs four segments and owns a portfolio that includes Pine-Sol, Liquid-Plumr, Glad bags, Brita filters, Kingsford charcoal, Hidden Valley dressings, Fresh Step cat litter, and Burt’s Bees. Over 80% of revenue is domestic. These are not brands that disappear when the economy gets choppy. Middle-class households cutting back on restaurant meals and tech upgrades do not stop buying disinfecting wipes. The cleaning aisle does not get discretionary. That recurring, almost automatic demand is the whole foundation of the income argument here, and it is the reason this stock keeps ending up on value screens even when the chart looks awful.

Slight tangent, but it matters: GOJO is a more interesting acquisition than the headline number suggests. Purell is not really a consumer product at its core. Hospitals buy it. Schools buy it. Office buildings have it mounted on every hallway wall. That is a professional hygiene channel with structurally higher margins and more durable demand than anything you find on a retail shelf. If Clorox integrates it cleanly, the long-term margin profile of this company looks meaningfully different in three years. The risk is that integration takes longer and costs more than modeled, which is exactly what the balance sheet is already telling you. Short-term debt stood at $1.59 billion as of March 2026. That is not dangerous for a company this size, but it is not nothing either.

The valuation math is straightforward. At 15 to 17x forward earnings, CLX is trading at a meaningful discount to the S&P 500’s roughly 21 to 22x forward multiple. The yield of 5.3% is the highest this stock has offered in years. Trailing 12-month net margin is 11.2%, up from 9.9% a year prior. Earnings growth over the same period came in at 8.9%. None of that screams broken business. It screams a business going through an expensive transition that the market has decided to price harshly.

Analysts are not in agreement on what comes next. Goldman Sachs is at Sell with an $83 target. Jefferies is at Buy with $139. The consensus across 19 analysts is Hold, average target near $105. That $56 spread between the high and low target is not typical for a consumer staples name. It reflects a genuine disagreement about whether the margin damage is permanent or temporary. Goldman’s argument centers on private label acceleration and structural input cost pressure. Jefferies is betting on brand resilience and GOJO upside. Both are coherent. Neither is obviously right yet.

The private label angle deserves more attention than it usually gets in the bull case. When grocery inflation stays elevated for an extended period, something shifts in shopper behavior. People try the store-brand trash bag once. It works fine. They do not go back. That erosion is slow and hard to see in any single quarter, but it compounds. Clorox’s brand equity is real and durable in categories like bleach and disinfecting wipes, where the Clorox name carries genuine consumer trust around germ-kill efficacy. It is less durable in categories like charcoal and salad dressing, where the private label alternative is close enough. That mix matters when you are modeling where margins settle long-term.

Quick snapshot of where things stand:

• Current price: ~$98 | 52-week high: $132
• Q3 FY2026 net sales: $1.67B (flat YoY)
• Adjusted EPS: $1.64 (beat by ~6%)
• Gross margin: 43.2% (down 140 bps)
• Organic sales: down 1%
• Full-year adjusted EPS guidance: $4.78–$4.98
• Annual dividend: $4.96/share | Yield: 5.3%
• 5-year average yield: 3.31%
• FCF margin: 11.1% (2-year avg)
• Net margin TTM: 11.2%
• Forward P/E: 15–17x vs. S&P ~21–22x
• Consecutive dividend raises: 48 years
• Short-term debt: $1.59B (March 2026)
• Analyst consensus: Hold | Avg target ~$105

What’s interesting is that the income case and the value case are actually separate arguments here, and they do not both need to be right for this to work. If you buy CLX near $98 and the stock goes nowhere for 18 months, you collected roughly $7.44 in dividends. If it drifts toward analyst consensus near $105, you made money two ways. The bear case requires believing that a 110-year-old company with category-dominant brands and 48 unbroken years of dividend raises has finally hit a structural wall. That is possible. It is just a higher-conviction call than most bears are making explicitly.

The CEO transition is the wildcard I keep coming back to. Not because it changes the business fundamentals, but because capital allocation decisions are going to matter a lot over the next two years. Whoever takes the top job will inherit a stretched balance sheet, a mid-integration acquisition, and a board that has to decide how aggressively to chase margin recovery versus how conservatively to manage debt. That decision tree will tell you a lot about where the dividend growth rate goes from here.

Watch Q4 FY2026. That is the number that starts to answer the real question.